Epstein Secrets

ng "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successfully • Competitive fees - 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACART CAPITAL LLC EFTA_R1_01138845 EFTA02295571 Return on Investment X

ety for Virology and a past president of the American Society for Microbiology. He is currently a member of the National Science Advisory Board for Biosecurity, and a member of the Board of Directors of CV Therapeutics, and Merck and Company. Robert Dow, BSc MBChB FRCP (Edln) Dr. Dow's current position is

ng "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successfully • Competitive fees — 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACARI CAPI I AL LL, EFTA00506150 Return on Investment Xenogen Jan-98

ety for Virology and a past president of the American Society for Microbiology. He is currently a member of the National Science Advisory Board for Biosecurity, and a member of the Board of Directors of CV Therapeutics, and Merck and Company. Robert Dow, BSc MBChB FRCP (Edin) Dr. Dow's current position is

ng "big game" • Short time & limited capital to profit/liquidity • I have hands-on experience doing this successfully • Competitive fees — 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACARI CAPI I AL LL, EFTA00506197 Advisory Board Thomas Shenk, • Dr. S

ety for Virology and a past president of the American Society for Microbiology. He is currently a member of the National Science Advisory Board for Biosecurity, and a member of the Board of Directors of CV Therapeutics, and Merck and Company. Robert Dow, BSc MBChB FRCP (Edin) Dr. Dow's current position is